nodes	percent_of_prediction	percent_of_DWPC	metapath
Bicalutamide—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.0756	0.109	CbGbCtD
Bicalutamide—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.0756	0.109	CbGbCtD
Bicalutamide—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0628	0.0906	CbGbCtD
Bicalutamide—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0628	0.0906	CbGbCtD
Bicalutamide—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0575	0.0828	CbGbCtD
Bicalutamide—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0575	0.0828	CbGbCtD
Bicalutamide—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0512	0.0738	CbGbCtD
Bicalutamide—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0482	0.0695	CbGbCtD
Bicalutamide—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0476	0.0686	CbGbCtD
Bicalutamide—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0326	0.0469	CbGbCtD
Bicalutamide—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.0317	0.0458	CbGbCtD
Bicalutamide—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0311	0.0448	CbGbCtD
Bicalutamide—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0277	0.0399	CbGbCtD
Bicalutamide—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0162	0.0234	CbGbCtD
Bicalutamide—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0153	0.0221	CbGbCtD
Bicalutamide—AR—FOXA1 transcription factor network—SCGB1A1—chronic obstructive pulmonary disease	0.00235	0.0472	CbGpPWpGaD
Bicalutamide—CYP3A4—Lidocaine metabolism—CYP1A2—chronic obstructive pulmonary disease	0.0022	0.0442	CbGpPWpGaD
Bicalutamide—Enzalutamide—ALB—chronic obstructive pulmonary disease	0.00203	1	CrCbGaD
Bicalutamide—CYP3A4—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.00194	0.0391	CbGpPWpGaD
Bicalutamide—AR—FOXA1 transcription factor network—SFTPD—chronic obstructive pulmonary disease	0.00178	0.0358	CbGpPWpGaD
Bicalutamide—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—chronic obstructive pulmonary disease	0.00159	0.032	CbGpPWpGaD
Bicalutamide—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A2—chronic obstructive pulmonary disease	0.00121	0.0243	CbGpPWpGaD
Bicalutamide—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A2—chronic obstructive pulmonary disease	0.0011	0.0221	CbGpPWpGaD
Bicalutamide—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A2—chronic obstructive pulmonary disease	0.0011	0.0221	CbGpPWpGaD
Bicalutamide—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—chronic obstructive pulmonary disease	0.00102	0.0205	CbGpPWpGaD
Bicalutamide—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A2—chronic obstructive pulmonary disease	0.001	0.0201	CbGpPWpGaD
Bicalutamide—AR—FOXA1 transcription factor network—SERPINA1—chronic obstructive pulmonary disease	0.00096	0.0193	CbGpPWpGaD
Bicalutamide—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.000876	0.0176	CbGpPWpGaD
Bicalutamide—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000807	0.0162	CbGpPWpGaD
Bicalutamide—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.000799	0.0161	CbGpPWpGaD
Bicalutamide—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.000797	0.016	CbGpPWpGaD
Bicalutamide—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.000727	0.0146	CbGpPWpGaD
Bicalutamide—CYP2D6—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000637	0.0128	CbGpPWpGaD
Bicalutamide—CYP3A4—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.000618	0.0124	CbGpPWpGaD
Bicalutamide—CYP2C19—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000579	0.0117	CbGpPWpGaD
Bicalutamide—CYP2C19—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000557	0.0112	CbGpPWpGaD
Bicalutamide—CYP2D6—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000533	0.0107	CbGpPWpGaD
Bicalutamide—CYP2C9—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000528	0.0106	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—RAPGEF3—chronic obstructive pulmonary disease	0.000517	0.0104	CbGpPWpGaD
Bicalutamide—CYP2D6—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000513	0.0103	CbGpPWpGaD
Bicalutamide—CYP2C9—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000508	0.0102	CbGpPWpGaD
Bicalutamide—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00048	0.00964	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—HDAC2—chronic obstructive pulmonary disease	0.000463	0.00931	CbGpPWpGaD
Bicalutamide—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000463	0.00931	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—HDAC2—chronic obstructive pulmonary disease	0.000458	0.00922	CbGpPWpGaD
Bicalutamide—CYP2C19—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	0.00043	0.00866	CbGpPWpGaD
Bicalutamide—CYP2C19—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000421	0.00847	CbGpPWpGaD
Bicalutamide—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000417	0.00838	CbGpPWpGaD
Bicalutamide—CYP2C19—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000405	0.00814	CbGpPWpGaD
Bicalutamide—CYP2D6—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	0.000396	0.00796	CbGpPWpGaD
Bicalutamide—CYP2D6—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000387	0.00779	CbGpPWpGaD
Bicalutamide—CYP2C9—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000384	0.00772	CbGpPWpGaD
Bicalutamide—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000379	0.00762	CbGpPWpGaD
Bicalutamide—CYP2D6—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000372	0.00749	CbGpPWpGaD
Bicalutamide—CYP2C9—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000369	0.00743	CbGpPWpGaD
Bicalutamide—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000363	0.0073	CbGpPWpGaD
Bicalutamide—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000348	0.00701	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—IL10—chronic obstructive pulmonary disease	0.000347	0.00699	CbGpPWpGaD
Bicalutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000346	0.00695	CbGpPWpGaD
Bicalutamide—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000335	0.00674	CbGpPWpGaD
Bicalutamide—CYP2C19—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000334	0.00671	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.000329	0.00661	CbGpPWpGaD
Bicalutamide—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000317	0.00124	CcSEcCtD
Bicalutamide—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000317	0.00124	CcSEcCtD
Bicalutamide—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000316	0.00124	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000316	0.00124	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000316	0.00124	CcSEcCtD
Bicalutamide—Neuropathy—Prednisone—chronic obstructive pulmonary disease	0.000316	0.00124	CcSEcCtD
Bicalutamide—CYP2C19—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000313	0.00629	CbGpPWpGaD
Bicalutamide—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000312	0.00122	CcSEcCtD
Bicalutamide—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000311	0.00122	CcSEcCtD
Bicalutamide—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000311	0.00122	CcSEcCtD
Bicalutamide—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.00031	0.00122	CcSEcCtD
Bicalutamide—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.00031	0.00122	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000309	0.00122	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000309	0.00121	CcSEcCtD
Bicalutamide—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.000308	0.00121	CcSEcCtD
Bicalutamide—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000308	0.00121	CcSEcCtD
Bicalutamide—CYP2D6—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000307	0.00617	CbGpPWpGaD
Bicalutamide—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000305	0.0012	CcSEcCtD
Bicalutamide—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000305	0.0012	CcSEcCtD
Bicalutamide—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000305	0.0012	CcSEcCtD
Bicalutamide—Ecchymosis—Prednisone—chronic obstructive pulmonary disease	0.000304	0.00119	CcSEcCtD
Bicalutamide—Infection—Formoterol—chronic obstructive pulmonary disease	0.000303	0.00119	CcSEcCtD
Bicalutamide—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000303	0.00119	CcSEcCtD
Bicalutamide—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000303	0.00609	CbGpPWpGaD
Bicalutamide—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.0003	0.00118	CcSEcCtD
Bicalutamide—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.0003	0.00118	CcSEcCtD
Bicalutamide—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.0003	0.00118	CcSEcCtD
Bicalutamide—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000299	0.00118	CcSEcCtD
Bicalutamide—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000299	0.00117	CcSEcCtD
Bicalutamide—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000299	0.00117	CcSEcCtD
Bicalutamide—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000299	0.00117	CcSEcCtD
Bicalutamide—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000299	0.00117	CcSEcCtD
Bicalutamide—Infection—Montelukast—chronic obstructive pulmonary disease	0.000297	0.00117	CcSEcCtD
Bicalutamide—AR—SIDS Susceptibility Pathways—SLC6A4—chronic obstructive pulmonary disease	0.000297	0.00597	CbGpPWpGaD
Bicalutamide—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000296	0.00116	CcSEcCtD
Bicalutamide—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000296	0.00116	CcSEcCtD
Bicalutamide—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000296	0.00116	CcSEcCtD
Bicalutamide—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000295	0.00116	CcSEcCtD
Bicalutamide—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000294	0.00115	CcSEcCtD
Bicalutamide—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000293	0.00115	CcSEcCtD
Bicalutamide—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000292	0.00115	CcSEcCtD
Bicalutamide—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.000292	0.00115	CcSEcCtD
Bicalutamide—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000291	0.00584	CbGpPWpGaD
Bicalutamide—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.00029	0.00114	CcSEcCtD
Bicalutamide—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000288	0.00113	CcSEcCtD
Bicalutamide—CYP2D6—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000288	0.00579	CbGpPWpGaD
Bicalutamide—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000286	0.00112	CcSEcCtD
Bicalutamide—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000283	0.00111	CcSEcCtD
Bicalutamide—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000283	0.00111	CcSEcCtD
Bicalutamide—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000282	0.00111	CcSEcCtD
Bicalutamide—Thrombophlebitis—Prednisone—chronic obstructive pulmonary disease	0.000282	0.00111	CcSEcCtD
Bicalutamide—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.000281	0.0011	CcSEcCtD
Bicalutamide—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.00028	0.0011	CcSEcCtD
Bicalutamide—CYP2C19—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000278	0.0056	CbGpPWpGaD
Bicalutamide—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000278	0.00109	CcSEcCtD
Bicalutamide—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000278	0.00109	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000278	0.00109	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000278	0.00109	CcSEcCtD
Bicalutamide—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000276	0.00108	CcSEcCtD
Bicalutamide—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000276	0.00108	CcSEcCtD
Bicalutamide—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000275	0.00554	CbGpPWpGaD
Bicalutamide—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000274	0.00108	CcSEcCtD
Bicalutamide—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000274	0.00108	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000272	0.00107	CcSEcCtD
Bicalutamide—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000272	0.00107	CcSEcCtD
Bicalutamide—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000272	0.00107	CcSEcCtD
Bicalutamide—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000271	0.00106	CcSEcCtD
Bicalutamide—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000271	0.00106	CcSEcCtD
Bicalutamide—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.00027	0.00106	CcSEcCtD
Bicalutamide—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	0.000269	0.00106	CcSEcCtD
Bicalutamide—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000268	0.00105	CcSEcCtD
Bicalutamide—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000268	0.00105	CcSEcCtD
Bicalutamide—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000268	0.00105	CcSEcCtD
Bicalutamide—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000267	0.00105	CcSEcCtD
Bicalutamide—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000266	0.00104	CcSEcCtD
Bicalutamide—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000265	0.00104	CcSEcCtD
Bicalutamide—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000264	0.00104	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000263	0.00103	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000263	0.00103	CcSEcCtD
Bicalutamide—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000263	0.00103	CcSEcCtD
Bicalutamide—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000263	0.00103	CcSEcCtD
Bicalutamide—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000263	0.00103	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000262	0.00103	CcSEcCtD
Bicalutamide—Pain—Formoterol—chronic obstructive pulmonary disease	0.000261	0.00102	CcSEcCtD
Bicalutamide—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000261	0.00102	CcSEcCtD
Bicalutamide—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000261	0.00102	CcSEcCtD
Bicalutamide—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000261	0.00102	CcSEcCtD
Bicalutamide—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.00026	0.00102	CcSEcCtD
Bicalutamide—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000259	0.00102	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000258	0.00101	CcSEcCtD
Bicalutamide—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000257	0.00101	CcSEcCtD
Bicalutamide—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000257	0.00101	CcSEcCtD
Bicalutamide—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000256	0.00101	CcSEcCtD
Bicalutamide—Pain—Montelukast—chronic obstructive pulmonary disease	0.000255	0.001	CcSEcCtD
Bicalutamide—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000255	0.001	CcSEcCtD
Bicalutamide—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000255	0.001	CcSEcCtD
Bicalutamide—CYP2C9—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000254	0.00511	CbGpPWpGaD
Bicalutamide—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000254	0.000997	CcSEcCtD
Bicalutamide—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000254	0.000997	CcSEcCtD
Bicalutamide—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000253	0.000995	CcSEcCtD
Bicalutamide—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000253	0.00509	CbGpPWpGaD
Bicalutamide—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000253	0.000992	CcSEcCtD
Bicalutamide—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000252	0.000991	CcSEcCtD
Bicalutamide—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000252	0.000988	CcSEcCtD
Bicalutamide—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000251	0.000987	CcSEcCtD
Bicalutamide—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000251	0.000987	CcSEcCtD
Bicalutamide—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000251	0.000986	CcSEcCtD
Bicalutamide—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.00025	0.000983	CcSEcCtD
Bicalutamide—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	0.00025	0.000983	CcSEcCtD
Bicalutamide—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.00025	0.000981	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000249	0.000979	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000249	0.000979	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000249	0.000976	CcSEcCtD
Bicalutamide—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000248	0.000975	CcSEcCtD
Bicalutamide—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000246	0.000967	CcSEcCtD
Bicalutamide—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000246	0.000967	CcSEcCtD
Bicalutamide—CYP2C19—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000246	0.00495	CbGpPWpGaD
Bicalutamide—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000244	0.000959	CcSEcCtD
Bicalutamide—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000243	0.0049	CbGpPWpGaD
Bicalutamide—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000242	0.000951	CcSEcCtD
Bicalutamide—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000242	0.000951	CcSEcCtD
Bicalutamide—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000241	0.000947	CcSEcCtD
Bicalutamide—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000241	0.000947	CcSEcCtD
Bicalutamide—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000241	0.000947	CcSEcCtD
Bicalutamide—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000241	0.000947	CcSEcCtD
Bicalutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000241	0.00484	CbGpPWpGaD
Bicalutamide—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.00024	0.000944	CcSEcCtD
Bicalutamide—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000238	0.000936	CcSEcCtD
Bicalutamide—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000238	0.000935	CcSEcCtD
Bicalutamide—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000238	0.000935	CcSEcCtD
Bicalutamide—CYP2C19—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000237	0.00478	CbGpPWpGaD
Bicalutamide—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000237	0.000932	CcSEcCtD
Bicalutamide—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000237	0.000932	CcSEcCtD
Bicalutamide—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000237	0.00093	CcSEcCtD
Bicalutamide—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000237	0.000929	CcSEcCtD
Bicalutamide—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000236	0.000927	CcSEcCtD
Bicalutamide—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000236	0.000927	CcSEcCtD
Bicalutamide—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.000236	0.000926	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000235	0.000925	CcSEcCtD
Bicalutamide—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000234	0.000918	CcSEcCtD
Bicalutamide—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000232	0.000913	CcSEcCtD
Bicalutamide—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	0.000232	0.000912	CcSEcCtD
Bicalutamide—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000229	0.000898	CcSEcCtD
Bicalutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000228	0.00458	CbGpPWpGaD
Bicalutamide—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000228	0.000894	CcSEcCtD
Bicalutamide—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000228	0.000894	CcSEcCtD
Bicalutamide—CYP2D6—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000226	0.00455	CbGpPWpGaD
Bicalutamide—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000225	0.000882	CcSEcCtD
Bicalutamide—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000225	0.000882	CcSEcCtD
Bicalutamide—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000224	0.000881	CcSEcCtD
Bicalutamide—CYP2C9—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000224	0.00451	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—SERPINE1—chronic obstructive pulmonary disease	0.000224	0.00451	CbGpPWpGaD
Bicalutamide—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000224	0.00088	CcSEcCtD
Bicalutamide—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000224	0.000879	CcSEcCtD
Bicalutamide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000221	0.00445	CbGpPWpGaD
Bicalutamide—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.00022	0.000864	CcSEcCtD
Bicalutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000219	0.00441	CbGpPWpGaD
Bicalutamide—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000219	0.000859	CcSEcCtD
Bicalutamide—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000219	0.000859	CcSEcCtD
Bicalutamide—CYP2D6—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000218	0.00439	CbGpPWpGaD
Bicalutamide—CYP2C9—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000216	0.00435	CbGpPWpGaD
Bicalutamide—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000216	0.000847	CcSEcCtD
Bicalutamide—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000216	0.000847	CcSEcCtD
Bicalutamide—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000215	0.000846	CcSEcCtD
Bicalutamide—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000215	0.000846	CcSEcCtD
Bicalutamide—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000214	0.000842	CcSEcCtD
Bicalutamide—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000212	0.000833	CcSEcCtD
Bicalutamide—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000211	0.00083	CcSEcCtD
Bicalutamide—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000209	0.000819	CcSEcCtD
Bicalutamide—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000209	0.000819	CcSEcCtD
Bicalutamide—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000208	0.000816	CcSEcCtD
Bicalutamide—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000207	0.000811	CcSEcCtD
Bicalutamide—AR—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.000206	0.00414	CbGpPWpGaD
Bicalutamide—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000204	0.000803	CcSEcCtD
Bicalutamide—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000204	0.0008	CcSEcCtD
Bicalutamide—CYP2C19—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000202	0.00407	CbGpPWpGaD
Bicalutamide—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000202	0.000792	CcSEcCtD
Bicalutamide—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000202	0.000792	CcSEcCtD
Bicalutamide—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000197	0.000776	CcSEcCtD
Bicalutamide—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000197	0.000775	CcSEcCtD
Bicalutamide—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000197	0.000774	CcSEcCtD
Bicalutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000195	0.00392	CbGpPWpGaD
Bicalutamide—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000194	0.000763	CcSEcCtD
Bicalutamide—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000194	0.000761	CcSEcCtD
Bicalutamide—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000194	0.000761	CcSEcCtD
Bicalutamide—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000192	0.000755	CcSEcCtD
Bicalutamide—Rash—Formoterol—chronic obstructive pulmonary disease	0.000192	0.000755	CcSEcCtD
Bicalutamide—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000192	0.000754	CcSEcCtD
Bicalutamide—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000192	0.000754	CcSEcCtD
Bicalutamide—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000192	0.000754	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—chronic obstructive pulmonary disease	0.000192	0.00386	CbGpPWpGaD
Bicalutamide—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000191	0.00075	CcSEcCtD
Bicalutamide—Headache—Formoterol—chronic obstructive pulmonary disease	0.000191	0.00075	CcSEcCtD
Bicalutamide—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000191	0.00075	CcSEcCtD
Bicalutamide—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.00019	0.000748	CcSEcCtD
Bicalutamide—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.00019	0.000748	CcSEcCtD
Bicalutamide—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.00019	0.000746	CcSEcCtD
Bicalutamide—Rash—Montelukast—chronic obstructive pulmonary disease	0.000188	0.00074	CcSEcCtD
Bicalutamide—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000188	0.000739	CcSEcCtD
Bicalutamide—Depression—Prednisone—chronic obstructive pulmonary disease	0.000188	0.000737	CcSEcCtD
Bicalutamide—Headache—Montelukast—chronic obstructive pulmonary disease	0.000187	0.000735	CcSEcCtD
Bicalutamide—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000185	0.000728	CcSEcCtD
Bicalutamide—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000185	0.000726	CcSEcCtD
Bicalutamide—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000184	0.000724	CcSEcCtD
Bicalutamide—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000184	0.000724	CcSEcCtD
Bicalutamide—CYP2C9—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000184	0.00371	CbGpPWpGaD
Bicalutamide—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000183	0.000719	CcSEcCtD
Bicalutamide—AR—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.000182	0.00366	CbGpPWpGaD
Bicalutamide—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000182	0.000713	CcSEcCtD
Bicalutamide—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000181	0.000713	CcSEcCtD
Bicalutamide—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000181	0.000712	CcSEcCtD
Bicalutamide—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000181	0.000711	CcSEcCtD
Bicalutamide—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000181	0.000711	CcSEcCtD
Bicalutamide—Headache—Salbutamol—chronic obstructive pulmonary disease	0.00018	0.000708	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—MMP1—chronic obstructive pulmonary disease	0.000179	0.00361	CbGpPWpGaD
Bicalutamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000179	0.00361	CbGpPWpGaD
Bicalutamide—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000179	0.0036	CbGpPWpGaD
Bicalutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000178	0.00358	CbGpPWpGaD
Bicalutamide—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000178	0.000698	CcSEcCtD
Bicalutamide—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000177	0.000697	CcSEcCtD
Bicalutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000175	0.00352	CbGpPWpGaD
Bicalutamide—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000175	0.000686	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—chronic obstructive pulmonary disease	0.000173	0.00349	CbGpPWpGaD
Bicalutamide—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000173	0.00347	CbGpPWpGaD
Bicalutamide—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000172	0.000675	CcSEcCtD
Bicalutamide—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000171	0.000672	CcSEcCtD
Bicalutamide—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.00017	0.000667	CcSEcCtD
Bicalutamide—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000169	0.000663	CcSEcCtD
Bicalutamide—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000165	0.000649	CcSEcCtD
Bicalutamide—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000162	0.000638	CcSEcCtD
Bicalutamide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000161	0.00323	CbGpPWpGaD
Bicalutamide—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.00016	0.000627	CcSEcCtD
Bicalutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000159	0.00321	CbGpPWpGaD
Bicalutamide—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000159	0.00319	CbGpPWpGaD
Bicalutamide—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000157	0.00316	CbGpPWpGaD
Bicalutamide—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000153	0.000602	CcSEcCtD
Bicalutamide—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000153	0.000599	CcSEcCtD
Bicalutamide—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000151	0.000593	CcSEcCtD
Bicalutamide—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000149	0.000587	CcSEcCtD
Bicalutamide—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000149	0.000586	CcSEcCtD
Bicalutamide—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000148	0.000582	CcSEcCtD
Bicalutamide—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000148	0.00298	CbGpPWpGaD
Bicalutamide—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000148	0.000581	CcSEcCtD
Bicalutamide—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000147	0.000577	CcSEcCtD
Bicalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000145	0.00291	CbGpPWpGaD
Bicalutamide—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000143	0.00287	CbGpPWpGaD
Bicalutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000142	0.00285	CbGpPWpGaD
Bicalutamide—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000141	0.000555	CcSEcCtD
Bicalutamide—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000136	0.000534	CcSEcCtD
Bicalutamide—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000136	0.000534	CcSEcCtD
Bicalutamide—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000134	0.000528	CcSEcCtD
Bicalutamide—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000132	0.000518	CcSEcCtD
Bicalutamide—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000131	0.000515	CcSEcCtD
Bicalutamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.00013	0.00262	CbGpPWpGaD
Bicalutamide—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00013	0.00262	CbGpPWpGaD
Bicalutamide—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000129	0.000508	CcSEcCtD
Bicalutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000129	0.0026	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—EGFR—chronic obstructive pulmonary disease	0.000129	0.00259	CbGpPWpGaD
Bicalutamide—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000127	0.000499	CcSEcCtD
Bicalutamide—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000125	0.000492	CcSEcCtD
Bicalutamide—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000125	0.00049	CcSEcCtD
Bicalutamide—CYP2C19—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000125	0.00251	CbGpPWpGaD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000124	0.000488	CcSEcCtD
Bicalutamide—CYP2C19—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000123	0.00248	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—CTGF—chronic obstructive pulmonary disease	0.000123	0.00247	CbGpPWpGaD
Bicalutamide—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000122	0.000478	CcSEcCtD
Bicalutamide—Oedema—Prednisone—chronic obstructive pulmonary disease	0.00012	0.000471	CcSEcCtD
Bicalutamide—Infection—Prednisone—chronic obstructive pulmonary disease	0.000119	0.000468	CcSEcCtD
Bicalutamide—Shock—Prednisone—chronic obstructive pulmonary disease	0.000118	0.000464	CcSEcCtD
Bicalutamide—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000118	0.000462	CcSEcCtD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000117	0.00236	CbGpPWpGaD
Bicalutamide—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000117	0.000458	CcSEcCtD
Bicalutamide—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000116	0.000456	CcSEcCtD
Bicalutamide—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000115	0.00231	CbGpPWpGaD
Bicalutamide—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000114	0.000449	CcSEcCtD
Bicalutamide—CYP2C9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000114	0.00229	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000113	0.00228	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	0.000112	0.00226	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000112	0.00226	CbGpPWpGaD
Bicalutamide—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000109	0.000429	CcSEcCtD
Bicalutamide—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000109	0.000429	CcSEcCtD
Bicalutamide—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000109	0.000426	CcSEcCtD
Bicalutamide—AR—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	0.000108	0.00217	CbGpPWpGaD
Bicalutamide—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000423	CcSEcCtD
Bicalutamide—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000415	CcSEcCtD
Bicalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000105	0.00211	CbGpPWpGaD
Bicalutamide—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000104	0.00041	CcSEcCtD
Bicalutamide—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000104	0.000409	CcSEcCtD
Bicalutamide—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000104	0.000409	CcSEcCtD
Bicalutamide—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000104	0.00209	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000104	0.00208	CbGpPWpGaD
Bicalutamide—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000103	0.000406	CcSEcCtD
Bicalutamide—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000103	0.000406	CcSEcCtD
Bicalutamide—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000103	0.000403	CcSEcCtD
Bicalutamide—CYP2C19—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000102	0.00206	CbGpPWpGaD
Bicalutamide—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	9.89e-05	0.000388	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	9.81e-05	0.000385	CcSEcCtD
Bicalutamide—Nausea—Prednisolone—chronic obstructive pulmonary disease	9.81e-05	0.000385	CcSEcCtD
Bicalutamide—Urticaria—Prednisone—chronic obstructive pulmonary disease	9.53e-05	0.000374	CcSEcCtD
Bicalutamide—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	9.53e-05	0.00192	CbGpPWpGaD
Bicalutamide—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	9.49e-05	0.000373	CcSEcCtD
Bicalutamide—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	9.49e-05	0.000373	CcSEcCtD
Bicalutamide—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	9.45e-05	0.0019	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	9.4e-05	0.00189	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	9.37e-05	0.00188	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	9.32e-05	0.00187	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	9.13e-05	0.00184	CbGpPWpGaD
Bicalutamide—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	8.84e-05	0.000347	CcSEcCtD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	8.76e-05	0.00176	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	8.64e-05	0.00174	CbGpPWpGaD
Bicalutamide—Asthenia—Prednisone—chronic obstructive pulmonary disease	8.61e-05	0.000338	CcSEcCtD
Bicalutamide—CYP2C19—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	8.52e-05	0.00171	CbGpPWpGaD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	8.52e-05	0.00171	CbGpPWpGaD
Bicalutamide—Pruritus—Prednisone—chronic obstructive pulmonary disease	8.49e-05	0.000333	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—EGFR—chronic obstructive pulmonary disease	8.43e-05	0.0017	CbGpPWpGaD
Bicalutamide—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	8.21e-05	0.000322	CcSEcCtD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	7.99e-05	0.00161	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	7.95e-05	0.0016	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	7.94e-05	0.0016	CbGpPWpGaD
Bicalutamide—Dizziness—Prednisone—chronic obstructive pulmonary disease	7.94e-05	0.000312	CcSEcCtD
Bicalutamide—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	7.88e-05	0.00158	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	7.84e-05	0.00158	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	7.83e-05	0.00158	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	7.83e-05	0.00157	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	7.77e-05	0.00156	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	7.77e-05	0.00156	CbGpPWpGaD
Bicalutamide—Vomiting—Prednisone—chronic obstructive pulmonary disease	7.63e-05	0.0003	CcSEcCtD
Bicalutamide—Rash—Prednisone—chronic obstructive pulmonary disease	7.57e-05	0.000297	CcSEcCtD
Bicalutamide—Dermatitis—Prednisone—chronic obstructive pulmonary disease	7.56e-05	0.000297	CcSEcCtD
Bicalutamide—CYP2C19—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	7.53e-05	0.00151	CbGpPWpGaD
Bicalutamide—Headache—Prednisone—chronic obstructive pulmonary disease	7.52e-05	0.000295	CcSEcCtD
Bicalutamide—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	7.5e-05	0.00151	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	7.42e-05	0.00149	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	7.41e-05	0.00149	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	7.3e-05	0.00147	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	7.24e-05	0.00146	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	7.2e-05	0.00145	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	7.14e-05	0.00144	CbGpPWpGaD
Bicalutamide—Nausea—Prednisone—chronic obstructive pulmonary disease	7.13e-05	0.00028	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	7.13e-05	0.00143	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—TP53—chronic obstructive pulmonary disease	7.08e-05	0.00142	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	6.99e-05	0.00141	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	6.92e-05	0.00139	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	6.86e-05	0.00138	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	6.83e-05	0.00137	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	6.77e-05	0.00136	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	6.66e-05	0.00134	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	6.32e-05	0.00127	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	6.23e-05	0.00125	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	6.14e-05	0.00124	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—APIP—chronic obstructive pulmonary disease	6.06e-05	0.00122	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—CTGF—chronic obstructive pulmonary disease	5.92e-05	0.00119	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	5.87e-05	0.00118	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—SERPINE1—chronic obstructive pulmonary disease	5.61e-05	0.00113	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	5.57e-05	0.00112	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	5.52e-05	0.00111	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—HDAC2—chronic obstructive pulmonary disease	5.52e-05	0.00111	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	5.2e-05	0.00105	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	5.12e-05	0.00103	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.78e-05	0.00096	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.71e-05	0.000947	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.53e-05	0.00091	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.46e-05	0.000898	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	4.32e-05	0.000869	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.01e-05	0.000807	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	3.98e-05	0.0008	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	3.94e-05	0.000792	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GC—chronic obstructive pulmonary disease	3.9e-05	0.000785	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.69e-05	0.000742	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.66e-05	0.000736	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	3.64e-05	0.000732	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.63e-05	0.00073	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	3.63e-05	0.00073	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	3.59e-05	0.000722	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	3.56e-05	0.000716	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.34e-05	0.000671	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.31e-05	0.000665	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.89e-05	0.000581	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—SERPINE1—chronic obstructive pulmonary disease	2.7e-05	0.000543	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.64e-05	0.00053	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.41e-05	0.000485	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	2.35e-05	0.000472	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.18e-05	0.000439	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.13e-05	0.000429	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	2.11e-05	0.000424	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.96e-05	0.000395	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.96e-05	0.000394	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.94e-05	0.000391	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.94e-05	0.00039	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	1.92e-05	0.000387	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	1.92e-05	0.000386	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.79e-05	0.00036	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.77e-05	0.000356	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.77e-05	0.000356	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	1.75e-05	0.000353	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.63e-05	0.000328	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.62e-05	0.000325	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.48e-05	0.000297	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.46e-05	0.000293	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.36e-05	0.000273	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.36e-05	0.000273	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.35e-05	0.000271	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.34e-05	0.00027	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.33e-05	0.000267	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.29e-05	0.000259	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.28e-05	0.000258	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	1.27e-05	0.000255	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.25e-05	0.000251	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.24e-05	0.000249	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.18e-05	0.000238	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.17e-05	0.000236	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	1.16e-05	0.000233	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.07e-05	0.000214	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.89e-06	0.000179	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.76e-06	0.000176	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	8.75e-06	0.000176	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	8.37e-06	0.000168	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.17e-06	0.000164	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	8.05e-06	0.000162	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	7.98e-06	0.00016	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.74e-06	0.000156	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	7.7e-06	0.000155	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	7.63e-06	0.000154	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	5.26e-06	0.000106	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	5.03e-06	0.000101	CbGpPWpGaD
